1.10Open0.10Pre Close6 Volume95 Open Interest17.50Strike Price655.00Turnover648.85%IV1.99%PremiumJul 19, 2024Expiry Date0.92Intrinsic Value100Multiplier-2DDays to Expiry0.33Extrinsic Value100Contract SizeAmericanOptions Type-0.7844Delta0.2681Gamma15.79Leverage Ratio-4.2815Theta0.0000Rho-12.39Eff Leverage0.0005Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet